Boston Scientific (BSX) stock price is $45.27, up 1.28% on the day, as of Nov 11, 2026. It has a market cap of $64.81Bn and a P/E ratio of 18.50, and is classified in the Medical Devices industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap64.81 Bn
P/E18.50
FCF (Yr)3.66 Bn
ROA (Yr)6.96
EV to EBIT15.38
Net Income (Yr)2.89 Bn
Enterprise Value60.48 Bn
Add ratio to table…
About
Boston Scientific Corporation is a global developer manufacturer and marketer of medical devices used in a broad range of interventional medical specialties. The company focuses on less invasive solutions that help physicians diagnose and treat cardiovascular respiratory digestive oncological neurological and urological conditions while improving patient outcomes and reducing healthcare costs.
Boston Scientific Corporation generates revenue by selling its medical devices to…
Boston Scientific Corporation is a global developer manufacturer and marketer of medical devices used in a broad range of interventional medical specialties. The company focuses on less invasive solutions that help physicians diagnose and treat cardiovascular respiratory digestive oncological neurological and urological conditions while improving patient outcomes and reducing healthcare costs.
Boston Scientific Corporation generates revenue by selling its medical devices to hospitals clinics outpatient facilities and medical offices worldwide. The company’s product portfolio includes endoscopic urological neuromodulation and cardiovascular devices such as stent systems catheters implantable pacemakers and neurostimulation platforms. Revenue is derived from direct sales forces distributors and group purchasing organizations that purchase its products for use in diagnostic and therapeutic procedures.
The company operates through the following segments: MedSurg and Cardiovascular.
The MedSurg segment includes the Endoscopy Urology and Neuromodulation business units which develop and manufacture minimally invasive devices for gastrointestinal pancreaticobiliary urological neurological and pain management applications.
The Cardiovascular segment comprises Interventional Cardiology and Vascular Therapies Watchman Electrophysiology and Cardiac Rhythm Management units which provide technologies for coronary peripheral venous disease treatment left atrial appendage closure heart rhythm disorders and implantable cardiac devices.
Boston Scientific Corporation holds a strong position in the global medical device industry competing with large diversified manufacturers and specialized niche players. The company’s competitive advantages stem from its ability to deliver differentiated clinical and economic outcomes ease of use reliability and physician familiarity. Its strategy of acquiring innovative technologies investing in research and development and expanding into high growth adjacencies supports its market leadership.
The company serves hospitals clinics outpatient facilities medical offices and group purchasing organizations in over 127 countries. Its customers include health care providers that rely on its devices for diagnostic therapeutic and surgical procedures across multiple specialties.
Sector:HealthcareSector rationaleBoston Scientific is a developer and manufacturer of medical devices, such as stent systems, catheters, and pacemakers, which are core products of the Healthcare sector. Its revenue is derived from selling these diagnostic and therapeutic tools to hospitals, clinics, and medical offices.Industry:Medical DevicesMedical DevicesPrimaryBoston Scientific designs and manufactures therapeutic and surgical medical devices, including stent systems, catheters, implantable pacemakers, and neurostimulation platforms. These products are sold to hospitals and clinics for use in cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions.Classified using BQ-MICSCIK: 0000885725
Bull & bear
Investment Thesis
▲ Bull case
Boston Scientific's FARAPULSE pulsed field ablation platform is demonstrating transformative clinical outcomes that are accelerating adoption beyond initial projections, particularly in the persistent atrial fibrillation population, which represents a significant unmet medical need and a major growth opportunity. The AVANT GUARD trial demonstrated statistical superiority of FARAPULSE over anti-arrhythmic drugs with significantly higher primary effectiveness, and real-world data shows redo rates after de novo persistent AF ablation have fallen into single-digit levels, indicating durable efficacy. This clinical validation, combined with the integration of OPAL HDx mapping and the upcoming FARAPOINT PFA catheter launch, positions the company to expand its addressable market in EP substantially, with global PFA penetration projected to grow from 50% at year-end 2025 to approximately 80% by 2028, driven by technological advancements and expanding clinical evidence that support broader patient access and reimbursement.
The concomitant WATCHMAN and FARAPULSE procedure (FARAWATCH) is emerging as a powerful growth catalyst that is underappreciated by the market, with management indicating that 25% of U.S. WATCHMAN procedures are already being performed concomitantly exiting 2025, and the potential for this to double by 2028. This trend is reinforced by strong clinical evidence from the OPTION-A trial and real-world data from the ALIGN-AF study, which confirms the safety and efficacy of combined procedures without compromising acute success. The FARAWATCH approach not only increases procedural volume and revenue per case but also strengthens customer loyalty and creates a defensible ecosystem that leverages Boston Scientific's leadership in both WATCHMAN (over 600,000 cumulative patients) and FARAPULSE, driving sustained mid-teens growth in WATCHMAN and accelerating EP market share gains through bundled solutions that address both stroke prevention and rhythm control in a single setting.
Boston Scientific's strategic investments in high-growth adjacencies, particularly the agreement to acquire Nalu Medical for peripheral nerve stimulation and the $1.5 billion investment in MiRus for access to the nickel-free SIEGEL TAVR system, are creating multi-year growth platforms that are not yet fully reflected in current guidance. The Nalu acquisition expands the neuromodulation portfolio into a large, underserved pain market with solid Medicare reimbursement and improving commercial payer coverage, complementing the recently acquired Relievant SI business and strengthening the company's position in peripheral nerve pain—a segment with minimal competition. Simultaneously, the MiRus investment provides an exclusive option to acquire a differentiated TAVR technology built on a proprietary rhenium alloy with potential advantages in delivery (8 French sheath, 50% smaller than competitors) and hemodynamics, positioning Boston Scientific to re-enter the TAVR market with a next-generation offering that could capture share from established players as the SIEGEL valve advances through the STAR pivotal trial targeting up to 1,025 patients. These moves align with the company's capital allocation priority of tuck-in M&A in high-growth areas and are expected to contribute meaningfully to long-range organic growth targets of 10%+ annually from 2026-2028.
Boston Scientific's FARAPULSE pulsed field ablation platform is demonstrating transformative clinical outcomes that are accelerating adoption beyond initial projections, particularly in the persistent atrial fibrillation population, which represents a significant unmet medical need and a major growth opportunity. The AVANT GUARD trial demonstrated statistical superiority of FARAPULSE over anti-arrhythmic drugs with significantly higher primary effectiveness, and real-world data shows redo rates after de novo persistent AF ablation have fallen into single-digit levels, indicating durable efficacy. This clinical validation, combined with the integration of OPAL HDx mapping and the upcoming FARAPOINT PFA catheter launch, positions the company to expand its addressable market in EP substantially, with global PFA penetration projected to grow from 50% at year-end 2025 to approximately 80% by 2028, driven by technological advancements and expanding clinical evidence that support broader patient access and reimbursement.
The concomitant WATCHMAN and FARAPULSE procedure (FARAWATCH) is emerging as a powerful growth catalyst that is underappreciated by the market, with management indicating that 25% of U.S. WATCHMAN procedures are already being performed concomitantly exiting 2025, and the potential for this to double by 2028. This trend is reinforced by strong clinical evidence from the OPTION-A trial and real-world data from the ALIGN-AF study, which confirms the safety and efficacy of combined procedures without compromising acute success. The FARAWATCH approach not only increases procedural volume and revenue per case but also strengthens customer loyalty and creates a defensible ecosystem that leverages Boston Scientific's leadership in both WATCHMAN (over 600,000 cumulative patients) and FARAPULSE, driving sustained mid-teens growth in WATCHMAN and accelerating EP market share gains through bundled solutions that address both stroke prevention and rhythm control in a single setting.
Boston Scientific's strategic investments in high-growth adjacencies, particularly the agreement to acquire Nalu Medical for peripheral nerve stimulation and the $1.5 billion investment in MiRus for access to the nickel-free SIEGEL TAVR system, are creating multi-year growth platforms that are not yet fully reflected in current guidance. The Nalu acquisition expands the neuromodulation portfolio into a large, underserved pain market with solid Medicare reimbursement and improving commercial payer coverage, complementing the recently acquired Relievant SI business and strengthening the company's position in peripheral nerve pain—a segment with minimal competition. Simultaneously, the MiRus investment provides an exclusive option to acquire a differentiated TAVR technology built on a proprietary rhenium alloy with potential advantages in delivery (8 French sheath, 50% smaller than competitors) and hemodynamics, positioning Boston Scientific to re-enter the TAVR market with a next-generation offering that could capture share from established players as the SIEGEL valve advances through the STAR pivotal trial targeting up to 1,025 patients. These moves align with the company's capital allocation priority of tuck-in M&A in high-growth areas and are expected to contribute meaningfully to long-range organic growth targets of 10%+ annually from 2026-2028.
Boston Scientific's Watchman device is facing a structural shift in procedure patterns that is undermining its historical growth trajectory, as declining uptake of standalone procedures is being driven by physicians increasingly combining Watchman with other heart treatments during a single visit, rather than performing it as a standalone procedure. CEO Michael Mahoney explicitly warned at the Bernstein conference that this trend is leading to flat dollar growth expectations for Watchman from Q1 to Q2 2026 and likely into Q3, directly contradicting prior assumptions of sustained high-growth contribution from the franchise. This behavioral change among electrophysiologists and interventional cardiologists reduces procedural volume and revenue per case, as concomitant procedures—while growing—do not fully offset the decline in standalone usage, and the company is now questioning the long-term growth rate of Watchman, which had been a cornerstone of its cardiovascular growth story and a key driver behind its 20% LRP market CAGR assumption.
The electrophysiology business is experiencing faster-than-expected market share losses due to intensified competition from Medtronic, Johnson & Johnson, and Abbott, which is eroding the mixed benefit that management had anticipated at the start of the year, as CFO Jonathan Monson acknowledged. Despite strong underlying market growth in PFA and ablation therapies, Boston Scientific's inability to maintain or grow its share in this high-growth segment threatens to cap the upside from its EP franchise, particularly as the business anniverves against exceptional prior-year performance and faces increasing competitive pressure in both the U.S. and international markets. This share erosion is particularly concerning given that EP sales grew 63% in Q3 2025, setting a high bar for continued outperformance, and any deceleration in growth—or worse, absolute decline—would significantly impact overall company performance, especially since EP has been a primary driver of both revenue and margin expansion through favorable product mix.
Urology segment performance remains persistently below expectations, with Axonics specifically cited as underperforming due to post-commercial disruption challenges, and management's outlook for improvement is contingent on operational enhancements that have yet to materialize, creating uncertainty around a key international growth lever. Although Urology showed 27% operational growth in Q3 2025, this was largely driven by international business and Stone Management, with organic growth of only 5%, and Axonics—the company's investment in sacral neuromodulation—continues to lag, requiring focused efforts on strengthening the commercial team, patient activation, and globalization opportunities. The segment's reliance on international contributions and the lack of clear near-term catalysts for Axonics recovery raise concerns about its ability to contribute meaningfully to long-term growth, especially as management has reiterated that Urology growth will improve throughout 2026 only if commercial execution improves, which remains unproven and introduces execution risk into a segment that was expected to be a more reliable contributor to the company's diversified growth profile.
Boston Scientific's Watchman device is facing a structural shift in procedure patterns that is undermining its historical growth trajectory, as declining uptake of standalone procedures is being driven by physicians increasingly combining Watchman with other heart treatments during a single visit, rather than performing it as a standalone procedure. CEO Michael Mahoney explicitly warned at the Bernstein conference that this trend is leading to flat dollar growth expectations for Watchman from Q1 to Q2 2026 and likely into Q3, directly contradicting prior assumptions of sustained high-growth contribution from the franchise. This behavioral change among electrophysiologists and interventional cardiologists reduces procedural volume and revenue per case, as concomitant procedures—while growing—do not fully offset the decline in standalone usage, and the company is now questioning the long-term growth rate of Watchman, which had been a cornerstone of its cardiovascular growth story and a key driver behind its 20% LRP market CAGR assumption.
The electrophysiology business is experiencing faster-than-expected market share losses due to intensified competition from Medtronic, Johnson & Johnson, and Abbott, which is eroding the mixed benefit that management had anticipated at the start of the year, as CFO Jonathan Monson acknowledged. Despite strong underlying market growth in PFA and ablation therapies, Boston Scientific's inability to maintain or grow its share in this high-growth segment threatens to cap the upside from its EP franchise, particularly as the business anniverves against exceptional prior-year performance and faces increasing competitive pressure in both the U.S. and international markets. This share erosion is particularly concerning given that EP sales grew 63% in Q3 2025, setting a high bar for continued outperformance, and any deceleration in growth—or worse, absolute decline—would significantly impact overall company performance, especially since EP has been a primary driver of both revenue and margin expansion through favorable product mix.
Urology segment performance remains persistently below expectations, with Axonics specifically cited as underperforming due to post-commercial disruption challenges, and management's outlook for improvement is contingent on operational enhancements that have yet to materialize, creating uncertainty around a key international growth lever. Although Urology showed 27% operational growth in Q3 2025, this was largely driven by international business and Stone Management, with organic growth of only 5%, and Axonics—the company's investment in sacral neuromodulation—continues to lag, requiring focused efforts on strengthening the commercial team, patient activation, and globalization opportunities. The segment's reliance on international contributions and the lack of clear near-term catalysts for Axonics recovery raise concerns about its ability to contribute meaningfully to long-term growth, especially as management has reiterated that Urology growth will improve throughout 2026 only if commercial execution improves, which remains unproven and introduces execution risk into a segment that was expected to be a more reliable contributor to the company's diversified growth profile.